Navigation Links
Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
Date:6/29/2009

--Dr. Sherman also elected President of the Drug Information Association (DIA)--

NORTHBROOK, Ill., June 29 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced the appointment of Jeffrey W. Sherman, M.D., F.A.C.P., as its executive vice president and chief medical officer.

Dr. Sherman brings more than 20 years of pharmaceutical experience to Horizon and will lead the regulatory and clinical strategy for Horizon's investigational therapies for mild-to-moderate arthritis and pain, including HZT-501, a fixed-dose combination tablet containing the most prescribed non-steroidal anti-inflammatory drug (NSAID), ibuprofen, with a high dose of the most potent H2 antagonist, famotidine. HZT-501 was shown to significantly reduce the incidence of NSAID-induced upper gastrointestinal ulcers in patients with mild-to-moderate pain in two Phase 3 studies.

Dr. Sherman joins Horizon from IDM Pharma, which was recently purchased by Takeda Pharmaceuticals Limited, where he led the clinical, regulatory, and development teams that secured European Commission approval for MEPACT(R) (mifamurtide, L-MTP-PE), a treatment for non-metastatic, resectable osteosarcoma. Prior to IDM Pharma, Dr. Sherman served as vice president of clinical science at Takeda Global Research & Development Center, Inc., a subsidiary of Takeda Pharmaceutical Company Limited, where he was focused on developing Takeda's oncology pipeline. Dr. Sherman also held the position of chief medical officer and executive vice president at NeoPharm, Inc., and held numerous research development and marketing roles at Searle/Pharmacia, including responsibility for the COX-2 (Celebrex) oncology program.

"Dr. Sherman has significant experience in the biotechnology and pharmaceutical industry, with a proven track record of success in bringing drugs through the regulatory process," said Timothy P. Walbert, president and chief executive officer of Horizon Therapeutics. "Dr. Sherman will oversee the preparation and submission of the HZT-501 regulatory applications to U.S. and European regulatory authorities, while helping us manage the clinical development of our other pain therapies."

In addition to his Horizon appointment, Dr. Sherman was recently elected President of the Drug Information Association (DIA), a global, nonprofit, multidisciplinary, professional association of approximately 18,000 members which provides a neutral forum for sharing information that optimizes the process of drug development and lifecycle management. He has been a member of the DIA Board of Directors for nearly seven years and in 2001, received the association's "Outstanding Service Award."

About Horizon Therapeutics

Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of mild-to-moderate pain and arthritis. Horizon's clinical portfolio includes innovative combination therapies in early- and late-stage development that are designed to improve safety, efficacy and patient compliance. For more information about the company and its products, please visit www.horizontherapeutics.com.


'/>"/>
SOURCE Horizon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AGA Institute and Horizon Therapeutics Launch Connect to Protect Program to Educate Physicians and Consumers on Risks Associated With NSAID Use
2. Horizon Therapeutics Selected to Present at InsideVentures Debut Investor Conference March 25-26, Santa Barbara, California
3. Horizon Therapeutics Announces Senior Management Appointments
4. Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
5. Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
6. Horizon Therapeutics to Present at UBS Global Life Sciences Conference
7. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
8. BioHorizons Global Symposium 2008 Combines Record Attendance with Groundbreaking Technology
9. BioHorizons Announces the Purchase of Implant Logic Systems
10. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
11. Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... 22, 2017 , ... Pharma and biotech consulting firm ... Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins brings 14 years ... than a decade with leading market research firm, GfK. He began his pharma ...
(Date:2/22/2017)... Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2017 ... ) today announced its financial results for the ... "Our annual 2016 financial results reflect continued ... earnings exceeded $700 million," said Martine Rothblatt, Ph.D., ... financial results strengthen our ability to develop and ...
(Date:2/21/2017)... , Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... and operational results for the three months ended December 31, ... -based life sciences and diagnostics company that develops and ... ... continue to build on the commercial milestones achieved in fiscal ...
(Date:2/21/2017)... ... February 21, 2017 , ... Vortex Biosciences announced ... automated benchtop system for collecting intact circulating tumor cells (CTCs) that are shed ... Medicine Tri Conference (Tri-Con) Annual Meeting 2017 (February 19–24 San Francisco). , The ...
Breaking Biology Technology:
(Date:2/16/2017)... 16, 2017  Genos, a community for personal ... has received Laboratory Accreditation from the College of ... to laboratories that meet stringent requirements around quality, ... processes. "Genos is committed to maintaining ... We,re honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
Breaking Biology News(10 mins):